Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: Results from cancer and group B 9066

Cancer

Volumn 104, Issue 8, 2005, Pages 1580-1589

  Peppercorn, Jeffrey ^a   Herndon II, James ^b   Kornblith, Alice B ^a   Peters, William ^c   Ahles, Tim ^d   Vredenburgh, James ^e   Schwartz, Gary ^d   Shpall, Elizabeth ^f   Hurd, David D ^g   Holland, Jimmie ^h   Winer, Eric ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c Adherex Technologies Inc   (United States)

^d NORRIS COTTON CANCER CENTER   (United States)

^e DUKE CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Assessment scales; Autologous stem cell support; Breast carcinoma; High dose chemotherapy; Quality of life

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FUNCTIONAL LIVING INDEX CANCER; HUMAN; MAJOR CLINICAL STUDY; MCCORKLE SYMPTOM DISTRESS SCALE; PRIORITY JOURNAL; PSYCHOSOCIAL ADJUSTMENT TO ILLNESS SCALE SELF REPORT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOCIAL STATUS; WELLBEING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 26444477289     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21363     Document Type: Article

References (32)

1. Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M. Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001;37:1123-1131.
2. Buzdar AU, Kau SW, Hortobagyi GN, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992;69:448-452.
3. Walker MJ, Osborne MD, Young DC, Schneebaum S, La Valle GJ, Farrar WB. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995;169:575-579.
4. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368-1376.
5. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132-1143.
6. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.
7. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose, sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol. 1997;15:2312-2321.
8. Canellos GP. Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? J Clin Oncol. 1997;15:3169-3170.
9. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary beast cancer: a report of CALBG 9082, SWOG 9114, and NCIC MA-13. J Clin. Oncol. 2005;23:2191-2200.
10. Kornblith AB, Holland JC. Model for quality-of-life research from the Cancer and Leukemia Group B: the telephone interview, conceptual approach to measurement, and theoretical framework. J Natl Cancer Inst Monogr. 1996;20:55-62.
11. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984;2:472-483.
12. Clinch J. The Functional Living Index-Cancer: ten years later. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996:215-225.
13. Morrow GR, Lindke I, Black P. Measurement of quality of life in patients: psychometric analyses of the Functional Living Index-Cancer (FLIC). Qual Life Res. 1992;1:287-296.
14. Derogatis LR. The Psychosocial Adjustment to Illness Scale (PAIS). J Psychosom Res. 1986;30:77-91.
15. McCorkle R. The measurement of symptom distress. Semin Oncol Nurs. 1987;3:248-256.
16. Holland JC, Kornblith AB, Cella DF, et al. A sociodemographic data collection model for cooperative clinical trials [abstract]. Proc Am Soc Clin Oncol. 1992;11:157.
17. Winer EP, Lindley C, Hardee M, et al. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psychooncology. 1999;8:167-176.
18. Del Mastro L, Costantini M, Morasso G, et al. Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. Eur J Cancer. 2002;38:359-366.
19. Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol. 2002;3:620-628.
20. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356:1384-1391.
21. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7-16.
22. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000;92:225-233.
23. Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol. 2002;13:689-698.
24. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000;342:1069-1076.
25. Lotz JP, Cure H, Janvier M, et al. [Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04]. Hematol Cell Ther. 1999;41:71-74.
26. Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica. 2003;88:201-211.
27. Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med. 2003;349:80-82.
28. Brandberg Y, Michelson H, Nilsson B, et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol. 2003;21:3659-3664.
29. Hann DM, Garovoy N, Finkelstein B, Jacobsen PB, Azzarello LM, Fields KK. Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: a longitudinal comparative study. J Pain Symptom Manage. 1999;17:311-319.
30. Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol. 2002;13:209-217.
31. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized Phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21:843-850.
32. Morasso G, Costantini M, Baracco G, Borreani C, Capelli M. Assessing psychological distress in cancer patients: validation of a self-administered questionnaire. Oncology. 1996;53:295-302.